平野医薬ニュース 第 266 号 12/12 ２０１２．１２ Ｎ o.２６６ ◆左室駆出率の保持された心不全における アンジオテンシン受容体･ネプリライシン阻害薬 LCZ696◆

Source URL: www.hirano-pharmacy.co.jp

Novartis Pharmaceuticals Canada Inc. 385 Bouchard Blvd. Dorval, Quebec Canada H9S 1A9 www.novartis.ca

Source URL: www.novartis.ca

• Anatomy
• Combination drugs
• Enantiopure drugs
• Novartis
• LCZ696
• Heart failure
• Health care in Canada
• Enalapril
• Management of heart failure
• Pharmacology
• Medicine
• ACE inhibitors

MEDIA STATEMENT • MEDIA STATEMENT • MEDIA STATEMENT Investigational heart failure medicine LCZ696 (sacubitril/valsartan) receives Promising Innovative Medicine designation in the UK PIM designation is the first s

Source URL: preview.thenewsmarket.com

• Organic chemistry
• Amides
• Novartis
• Carboxylic acids
• Heart diseases
• Valsartan
• Heart failure
• Enalapril
• LCZ696
• Chemistry
• Pharmacology
• ACE inhibitors

Novartis Pharmaceuticals Canada Inc. 385 Bouchard Blvd. Dorval, Quebec Canada H9S 1A9

Source URL: www.novartis.ca

• Anatomy
• Combination drugs
• Enantiopure drugs
• Prodrugs
• Antihypertensive agents
• Heart failure
• Enalapril
• Novartis
• LCZ696
• Pharmacology
• Medicine
• ACE inhibitors

Long term efficacy and safety comparison of the angiotensin receptor neprilysin inhibitor (ARNi), LCZ696, and valsartan, in patients with heart failure and preserved ejection fraction: A randomized, double blind, morbidi

Source URL: www.hfsa.org

• Angiotensin II receptor antagonists
• Amides
• Novartis
• Tetrazoles
• Valsartan
• Brain natriuretic peptide
• Heart failure
• N-terminal prohormone of brain natriuretic peptide
• Atrial fibrillation
• Chemistry
• Medicine
• Anatomy